Libtayo

Cemiplimab, the active ingredient in Libtayo, is a monoclonal antibody presented as an injection solution for intravenous use. It treats certain skin cancers and lung cancer in adult patients.\n\nGNH India supplies Libtayo as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

Libtayo (cemiplimab) is a PD‑1 inhibitor used in oncology to target immune checkpoint pathways.\n\n- Cutaneous squamous cell carcinoma: indicated for locally advanced or metastatic disease, improving progression‑free survival.\n- Advanced basal cell carcinoma: used when disease is not amenable to curative surgery or radiation, providing tumor control.\n- Non‑small cell lung cancer: indicated for metastatic disease with high PD‑L1 expression, extending overall survival.

Cemiplimab may cause a range of adverse reactions, varying from mild to severe.\n\nCommon Side Effects:\n- Fatigue\n- Rash or pruritus\n- Diarrhea\n- Nausea\n- Infusion‑related reactions (fever, chills)\n- Decreased appetite\n\nSerious or Rare Side Effects:\n- Immune‑mediated pneumonitis\n- Hepatitis or severe liver injury\n- Colitis or severe gastrointestinal inflammation\n- Endocrine disorders (thyroiditis, adrenal insufficiency)\n- Severe skin reactions (Stevens‑Johnson syndrome)\n- Anaphylaxis or severe infusion reactions

Before initiating therapy, clinicians should assess patient suitability and monitor for immune‑related events.\n\n- Monitor for immune‑related adverse events: watch for signs of pneumonitis, hepatitis, colitis, and endocrinopathies.\n- Assess baseline organ function: evaluate liver, kidney and thyroid status prior to treatment.\n- Avoid live vaccines: immunosuppression may reduce vaccine efficacy and increase infection risk.\n- Pregnancy and breastfeeding: safety not established; use only if potential benefit justifies the risk.\n- Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cemiplimab can interact with other agents that affect immune function or hemostasis.\n\nMajor Interactions (Avoid):\n- Concurrent systemic immunosuppressants: may diminish therapeutic effect.\n- Live attenuated vaccines: increased risk of infection.\n- Other PD‑1/PD‑L1 inhibitors: additive immune activation risk.\n\nModerate Interactions (Monitor Closely):\n- Corticosteroids: may require dose adjustment to balance efficacy and toxicity.\n- Anticoagulants: monitor for bleeding if immune‑mediated thrombocytopenia occurs.\n- CYP450 substrates: generally low interaction but monitor if hepatic function changes.